Christina Lam
Psychiatric/Mental Health · Coronado, CANPI 1700171436
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.1% of the total across 1,136 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,136 payments — averaging $21.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$4K
- Alkermes, Inc.$3K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Neurocrine Biosciences, Inc.$2K
- Teva Pharmaceuticals USA, Inc.$2K
- plus $10K from 27 others
What the payments were for
- Food & beverage$23,70597%
- Education$7163%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 129 | $3,938 |
| Alkermes, Inc. | 103 | $2,645 |
| Otsuka America Pharmaceutical, Inc. | 106 | $1,992 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 94 | $1,935 |
| Neurocrine Biosciences, Inc. | 97 | $1,913 |
| Teva Pharmaceuticals USA, Inc. | 58 | $1,681 |
| Sunovion Pharmaceuticals Inc. | 80 | $1,664 |
| AbbVie | 104 | $1,456 |
| Vanda Pharmaceuticals Inc. | 53 | $1,218 |
| Indivior Inc. | 52 | $957 |
| Lundbeck LLC | 49 | $947 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $648 |
| E.r. Squibb & Sons, L.L.C. | 24 | $591 |
| Supernus Pharmaceuticals, Inc. | 41 | $586 |
| Axsome Therapeutics, Inc. | 14 | $398 |
| Eisai Inc. | 26 | $380 |
| Ironshore Pharmaceuticals Inc. | 12 | $345 |
| Corium, LLC | 15 | $336 |
| Collegium Pharmaceutical, Inc. | 8 | $140 |
| Bausch Health US, LLC | 5 | $105 |
| TMS Neurohealth Centers Inc. | 1 | $98 |
| Idorsia Pharmaceuticals US Inc | 5 | $91 |
| Avanir Pharmaceuticals, Inc. | 4 | $72 |
| Almatica Pharma LLC | 3 | $66 |
| Noven Therapeutics, LLC | 2 | $40 |
| Pfizer | 2 | $38 |
| Lilly USA, LLC | 1 | $26 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Biogen | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Noven Pharmaceuticals, Inc. | 1 | $18 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Neos Therapeutics, LP | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,865
- INVEGA SUSTENNA$707
- ARISTADA$459
- INGREZZA$261
- INVEGA TRINZA$150
- COBENFY$126
- Fanapt$125
- REXULTI$122
- JORNAY PM$121
- ABILIFY MAINTENA$120
- Auvelity$120
- ARISTADA INITIO$115
- AUSTEDO$110
- CAPLYTA$109
How this compares
$24,421 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 349 | $1,245,785 |
| IngrezzaValbenazine Tosylate | 55 | $448,677 |
| AustedoDeutetrabenazine | 37 | $246,401 |
| CaplytaLumateperone Tosylate | 141 | $241,925 |
| PerserisRisperidone | 81 | $237,896 |
| Invega TrinzaPaliperidone Palmitate | 19 | $166,913 |
| FanaptIloperidone | 38 | $119,603 |
| VraylarCariprazine Hcl | 109 | $101,422 |
| RexultiBrexpiprazole | 58 | $85,362 |
| Abilify MaintenaAripiprazole | 26 | $76,888 |
| Austedo XrDeutetrabenazine | 26 | $67,981 |
| Olanzapine OdtOlanzapine | 671 | $55,470 |
| AristadaAripiprazole Lauroxil | 14 | $44,575 |
| Risperdal ConstaRisperidone Microspheres | 17 | $43,294 |
| LybalviOlanzapine/Samidorphan Malate | 27 | $42,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $3,938 | $1,455,992385 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,913 | $448,67755 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $1,681 | $314,38263 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,935 | $241,925141 claims |
| Indivior Inc.Perseris | $957 | $237,89681 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,992 | $162,25084 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $1,218 | $119,60338 claims |
| Alkermes, Inc.Aristada, Lybalvi, Vivitrol | $2,645 | $106,87352 claims |
| AbbVieVraylar | $1,456 | $101,422109 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $72 | $32,24521 claims |
| PfizerEffexor Xr | $38 | $11,39320 claims |
| Eisai Inc.Dayvigo | $380 | $9,51719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Coronado
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- Samantha PerkinsAnaheim$49K
- Yvette ElpidioOrange$43K
- Sarah KoLos Angeles$34K
- Jonathan LlamasPasadena$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.